Carotuximab
- Generic Name
- Carotuximab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1268714-50-6
- Unique Ingredient Identifier
- YB2EWE6139
- Indication
Investigated for use/treatment in solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Edwin Posadas, MD
- Target Recruit Count
- 100
- Registration Number
- NCT05534646
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Huntsman Cancer Institute and Hospital, Salt Lake City, Utah, United States
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Karen Reckamp, MD, MS
- Target Recruit Count
- 60
- Registration Number
- NCT05401110
- Locations
- 🇺🇸
Cedars-Sinai Cancer at The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Cedars-Sinai Cancer at Hunt Cancer Center - TMPNCC, Torrance, California, United States
🇺🇸Cedars-Sinai Cancer at Beverly Hills (THO), Beverly Hills, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath